Generic version of popular asthma inhaler wins FDA approval

Generic Version Of Popular Asthma Inhaler Wins FDA Approval part is one like these Health and Medical Updates categories, written over our scripter Linda Norton just as January 31, 2019, these blogpost can search much as that hastag approval, asthma, FDA, Generic, inhaler, popular, version, wins. I am pleased to satisfied you and providing this another essay concerning health as well as we always posting this blogpost frequenlty.


(HealthDay)—The first generic version of the widely used Advair Diskus inhaler for asthma and chronic obstructive pulmonary disease (COPD) has won U.S. Food and Drug Administration approval.

This approval “is part of our longstanding commitment to advance access to lower cost, high-quality generic alternatives,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research.

“People living with asthma and COPD know too well the critical importance of having access to the treatment they need to feel better. Today’s approval will bring more competition to the market, which will ultimately benefit the patients who rely on this drug,” Woodcock said Wednesday in an agency news release.

The new inhaler, from drug maker Mylan, contains fluticasone propionate and salmeterol inhalation powder. It’s approved for twice-daily treatment of asthma in patients aged 4 years and older. In COPD cases, it’s approved for maintenance treatment of airflow obstruction and reducing exacerbations.

Asthma is a chronic lung disease that inflames and narrows the airways. More than 26 million people in the United States are known to have it, including about 7 million children, the FDA noted.

COPD is a progressive lung disease that affects breathing and often worsens over time. Symptoms can include coughing that produces large amounts of mucus, wheezing, shortness of breath, and chest tightness.

The inhaler comes in three strengths: fluticasone propionate 100 mcg/salmeterol 50 mcg; fluticasone propionate 250 mcg/salmeterol 50 mcg; and fluticasone propionate 500 mcg/salmeterol 50 mcg.

In asthma patients, the most common side effects of this combination treatment are: upper-respiratory tract infection or inflammation; swelling in the back of the throat; hoarse voice or trouble speaking; oral thrush, also called candidiasis; bronchitis; cough; headaches; nausea and vomiting.

In COPD patients, the most common side effects are: pneumonia; oral candidiasis; throat irritation; hoarse voice or trouble speaking; viral respiratory infections; headaches; and musculoskeletal pain.

Salmeterol + fluticasone deemed safe for childhood asthma

More information:
SOURCE: U.S. Food and Drug Administration, news release, Jan. 30, 2019

The American Academy of Allergy, Asthma & Immunology has more on inhaled asthma medications.

Copyright © 2019 HealthDay. All rights reserved.

Generic version of popular asthma inhaler wins FDA approval (2019, January 31)
retrieved 31 January 2019

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

You can read other section health at our related post or you maybe want to check it immediately upon noted blogpost, I'm always updating this health paragraph routine for cue plus information together with ability in order to preserving our health plus living these healthy lifestyle. These section is updated on top of Linda Norton with these title Generic Version Of Popular Asthma Inhaler Wins FDA Approval.

Related posts of "Generic version of popular asthma inhaler wins FDA approval"

Study reveals complementary medicine use remains hidden to conventional medicine providers

Credit: CC0 Public Domain Research reveals that 1 in 3 complementary medicine (CM) users do not disclose their CM use to their medical providers, posing significant direct and indirect risks of adverse effects and harm due to unsafe concurrent use of CM and conventional medicine use. The first international systematic review conducted by researchers at...

Augmentation of labor with higher doses of oxytocin does not reduce rate of cesarean sections

Delayed labor increases the risk of a cesarean section, even among women who receive oxytocin for augmentation of labor. The rate of cesarean section among first-time mothers is not reduced if the administered dose is doubled either, according to a dissertation from Sahlgrenska Academy at the University of Gothenburg, Sweden. In her dissertation, Lotta Selin,...

Nullifying protein YTHDF1 enhances anti-tumor response

Artistic rendering of the surface of a human dendritic cell illustrating sheet-like processes that fold back onto the membrane surface. Credit: National Institutes of Health (NIH) Cancer immunotherapy—an approach that removes the barriers that protect cancer cells from a patient's immune system—has revolutionized the treatment of many cancer types. About 40 percent of melanoma patients,...

Ovarian cysts should be ‘watched’ rather than removed: study

Credit: CC0 Public Domain Women may not need to undergo surgery for non-cancerous ovarian cysts, avoiding potential surgical complications. This is the finding of new research, by a team of international scientists from institutions including Imperial College London and KU Leuven, published in The Lancet Oncology. The two-year study followed 1919 women from 10 different...

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.